Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | CDC25A | P30304 | 6/20 | 0.42 |
| ▸ | CDC25B | P30305 | 6/20 | 0.42 |
| ▸ | CDC25C | P30307 | 5/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | BID | P55957 | 3/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.40 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7166376 | 0.81 | PTPN1 (0.48) | FGFR1FGFR2FGFR4FGFR3PTPN1 | |
| SCHEMBL6707348 | 0.77 | PTPN1 (0.50) | PTPN1CDC25ACDC25BCDC25CALDH1A1 | |
| SCHEMBL27570013 | 0.76 | ALDH1A1 (0.51) | FGFR1FGFR2FGFR4FGFR3PTPN1 | |
| SCHEMBL8108866 | 0.75 | HSP90AA1 (0.54) | PTPN1HSP90AA1HSP90AB1MCL1NPC1 | |
| SCHEMBL29879118 | 0.74 | ALOX5 (0.55) | PTPN1KAT2BALDH1A1RAB9A | |
| SCHEMBL9857129 | 0.74 | ALOX5 (0.55) | PTPN1KAT2BALDH1A1RAB9A | |
| SCHEMBL9444208 | 0.74 | ALOX5 (0.55) | PTPN1KAT2BALDH1A1RAB9A | |
| SCHEMBL3273093 | 0.74 | ALOX5 (0.55) | PTPN1KAT2BALDH1A1RAB9A | |
| SCHEMBL30996030 | 0.74 | ALOX5 (0.55) | PTPN1KAT2BALDH1A1RAB9A | |
| SCHEMBL30245093 | 0.74 | ALOX5 (0.55) | PTPN1KAT2BALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-8148089-B2 | Alpha-synuclein kinase | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2012-04-03 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20110207796-A1 | ALPHA-SYNUCLEIN KINASE | ELAN PHARMA INTERNATIONAL LIMITED | 2011-08-25 | — | — | US | disclosed |
| EP-2247748-A2 | ALPHA-SYNUCLEIN KINASE | Elan Pharma International Limited (IE) | 2010-11-10 | — | — | EP | disclosed |
| US-20100143946-A1 | ALPHA-SYNUCLEIN KINASE | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2010-06-10 | — | — | US | disclosed |
| WO-2009103010-A2 | ALPHA-SYNUCLEIN KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| US-7553639-B2 | Alpha-synuclein kinase | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2009-06-30 | — | — | US | disclosed |
| US-20080300206-A1 | Alpha-Synuclein Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| EP-1989330-A2 | ALPHA-SYNUCLEIN KINASE | Elan Pharmaceuticals Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080160011-A1 | ALPHA-SYNUCLEIN KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2007089862-A2 | ALPHA-SYNUCLEIN KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885 |
| US-20110207796-A1 | ALPHA-SYNUCLEIN KINASE | SNCA, PLK2, LMTK2 | FGFR1 3295/4885FGFR2 2421/4885FGFR4 2943/4885 |
| US-20080300206-A1 | Alpha-Synuclein Kinase | SNCA, PLK2, LMTK2 | FGFR1 2387/4885FGFR2 1745/4885FGFR4 2592/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885 |
| US-20080160011-A1 | ALPHA-SYNUCLEIN KINASE | PLK2, GRK2, GRK6 | FGFR1 2221/4885FGFR2 1683/4885FGFR4 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.